HIGHLIGHTS
SUMMARY
This study examines the economic returns from biotechnology licenses from academic institutions to industry ("academic licenses") compared to those between for-profit corporate entities ("corporate licenses"). Specifically, this study compares the effective royalty rate, precommercial payments, and total deal value of academic licenses of drug-related biotechnologies with those of corporate licenses. The analysis then asks whether disparities in these economic terms are associated with differences in the licensee (biotech or pharma) or intrinsic terms of these licenses including the development stage of products covered by the license agreement, the activities anticipated under the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.